NewTimeSpace News: HENLIUS(02696.HK) issued an announcement on February 5, 2026, disclosing the core matters of the license agreement entered into with Eisai, which has taken effect since the date of signing. According to the announcement, HENLIUS grants Eisai an exclusive license for the commercialization of Hansoh® in Japan; it also grants Eisai a co-exclusive license for the development and manufacture of the product related to the treatment of oncology indications in the region.

In terms of payment, Eisai will pay an upfront fee of 75 million US dollars, followed by milestone payments of up to 80.01 million US dollars and 233.33 million US dollars based on the achievement of regulatory milestones and commercial sales milestones respectively. In addition, Eisai will pay a double-digit percentage royalty based on the annual net sales of the product in Japan.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.